^
    CANCER:

    Fallopian Tube Cancer

    No biomarker
    Fallopian Tube Cancer
    niraparib
    Sensitive: A1 - Approval
    No biomarker
    Fallopian Tube Cancer
    bevacizumab
    Sensitive: A1 - Approval
    No biomarker
    Fallopian Tube Cancer
    Mvasi (bevacizumab biosimilar)
    Sensitive: A1 - Approval
    No biomarker
    Fallopian Tube Cancer
    Aybintio (bevacizumab biosimilar)
    Sensitive: A1 - Approval
    No biomarker
    Fallopian Tube Cancer
    Onbevzi (bevacizumab biosimilar)
    Sensitive: A1 - Approval
    BRCA1 mutation
    Fallopian Tube Cancer
    rucaparib
    Sensitive: A1 - Approval
    BRCA2 mutation
    Fallopian Tube Cancer
    rucaparib
    Sensitive: A1 - Approval
    No biomarker
    Fallopian Tube Cancer
    rucaparib
    Sensitive: A1 - Approval
    BRCA2 mutation
    Fallopian Tube Cancer
    bevacizumab + olaparib
    Sensitive: A1 - Approval
    BRCA1 mutation
    Fallopian Tube Cancer
    bevacizumab + olaparib
    Sensitive: A1 - Approval
    HRD
    Fallopian Tube Cancer
    bevacizumab + olaparib
    Sensitive: A1 - Approval
    No biomarker
    Fallopian Tube Cancer
    olaparib
    Sensitive: A1 - Approval
    BRCA1 mutation
    Fallopian Tube Cancer
    niraparib
    Sensitive: A1 - Approval
    BRCA2 mutation
    Fallopian Tube Cancer
    niraparib
    Sensitive: A1 - Approval
    HRD
    Fallopian Tube Cancer
    niraparib
    Sensitive: A1 - Approval
    BRCA2 mutation
    Fallopian Tube Cancer
    olaparib
    Sensitive: A1 - Approval
    BRCA1 mutation
    Fallopian Tube Cancer
    olaparib
    Sensitive: A1 - Approval
    No biomarker
    Fallopian Tube Cancer
    carboplatin + micellar paclitaxel
    Sensitive: A1 - Approval
    BRCA1 mutation
    Fallopian Tube Cancer
    pamiparib
    Sensitive: A1 - Approval
    No biomarker
    Fallopian Tube Cancer
    Bevax (bevacizumab biosimilar)
    Sensitive: A1 - Approval
    BRCA2 mutation
    Fallopian Tube Cancer
    pamiparib
    Sensitive: A1 - Approval
    No biomarker
    Fallopian Tube Cancer
    CAPOX
    Sensitive: A2 - Guideline
    No biomarker
    Fallopian Tube Cancer
    sorafenib
    Sensitive: A2 - Guideline
    No biomarker
    Fallopian Tube Cancer
    topotecan
    Sensitive: A2 - Guideline
    No biomarker
    Fallopian Tube Cancer
    pegylated liposomal doxorubicin
    Sensitive: A2 - Guideline
    MSI-H/dMMR
    Fallopian Tube Cancer
    pembrolizumab
    Sensitive: A2 - Guideline
    NTRK3 fusion
    Fallopian Tube Cancer
    larotrectinib
    Sensitive: A2 - Guideline
    NTRK2 fusion
    Fallopian Tube Cancer
    larotrectinib
    Sensitive: A2 - Guideline
    NTRK1 fusion
    Fallopian Tube Cancer
    larotrectinib
    Sensitive: A2 - Guideline
    NTRK3 fusion
    Fallopian Tube Cancer
    entrectinib
    Sensitive: A2 - Guideline
    NTRK2 fusion
    Fallopian Tube Cancer
    entrectinib
    Sensitive: A2 - Guideline
    NTRK1 fusion
    Fallopian Tube Cancer
    entrectinib
    Sensitive: A2 - Guideline
    No biomarker
    Fallopian Tube Cancer
    etoposide oral
    Sensitive: A2 - Guideline
    No biomarker
    Fallopian Tube Cancer
    trametinib
    Sensitive: A2 - Guideline
    No biomarker
    Fallopian Tube Cancer
    fulvestrant
    Sensitive: A2 - Guideline
    No biomarker
    Fallopian Tube Cancer
    cisplatin + irinotecan
    Sensitive: A2 - Guideline
    No biomarker
    Fallopian Tube Cancer
    albumin-bound paclitaxel
    Sensitive: A2 - Guideline
    No biomarker
    Fallopian Tube Cancer
    pazopanib
    Sensitive: A2 - Guideline
    No biomarker
    Fallopian Tube Cancer
    bevacizumab + niraparib
    Sensitive: A2 - Guideline
    No biomarker
    Fallopian Tube Cancer
    vinorelbine tartrate
    Sensitive: A2 - Guideline
    No biomarker
    Fallopian Tube Cancer
    pemetrexed
    Sensitive: A2 - Guideline
    No biomarker
    Fallopian Tube Cancer
    paclitaxel
    Sensitive: A2 - Guideline
    No biomarker
    Fallopian Tube Cancer
    oxaliplatin
    Sensitive: A2 - Guideline
    No biomarker
    Fallopian Tube Cancer
    melphalan
    Sensitive: A2 - Guideline
    No biomarker
    Fallopian Tube Cancer
    irinotecan
    Sensitive: A2 - Guideline
    No biomarker
    Fallopian Tube Cancer
    ifosfamide
    Sensitive: A2 - Guideline
    No biomarker
    Fallopian Tube Cancer
    doxorubicin hydrochloride
    Sensitive: A2 - Guideline
    No biomarker
    Fallopian Tube Cancer
    cyclophosphamide
    Sensitive: A2 - Guideline
    No biomarker
    Fallopian Tube Cancer
    cisplatin
    Sensitive: A2 - Guideline
    No biomarker
    Fallopian Tube Cancer
    capecitabine
    Sensitive: A2 - Guideline
    No biomarker
    Fallopian Tube Cancer
    carboplatin + gemcitabine
    Sensitive: A2 - Guideline
    No biomarker
    Fallopian Tube Cancer
    cisplatin + paclitaxel
    Sensitive: A2 - Guideline
    No biomarker
    Fallopian Tube Cancer
    paclitaxel + ifosfamide
    Sensitive: A2 - Guideline
    No biomarker
    Fallopian Tube Cancer
    cisplatin + ifosfamide
    Sensitive: A2 - Guideline
    No biomarker
    Fallopian Tube Cancer
    carboplatin + ifosfamide
    Sensitive: A2 - Guideline
    No biomarker
    Fallopian Tube Cancer
    carboplatin
    Sensitive: A2 - Guideline
    No biomarker
    Fallopian Tube Cancer
    tamoxifen
    Sensitive: A2 - Guideline
    No biomarker
    Fallopian Tube Cancer
    leuprolide acetate
    Sensitive: A2 - Guideline
    No biomarker
    Fallopian Tube Cancer
    exemestane
    Sensitive: A2 - Guideline
    No biomarker
    Fallopian Tube Cancer
    letrozole
    Sensitive: A2 - Guideline
    No biomarker
    Fallopian Tube Cancer
    anastrozole
    Sensitive: A2 - Guideline
    No biomarker
    Fallopian Tube Cancer
    carboplatin + docetaxel
    Sensitive: A2 - Guideline
    No biomarker
    Fallopian Tube Cancer
    carboplatin + pegylated liposomal doxorubicin
    Sensitive: A2 - Guideline
    No biomarker
    Fallopian Tube Cancer
    5-fluorouracil + oxaliplatin
    Sensitive: A2 - Guideline
    No biomarker
    Fallopian Tube Cancer
    carboplatin + paclitaxel
    Sensitive: A2 - Guideline
    No biomarker
    Fallopian Tube Cancer
    BEP
    Sensitive: A2 - Guideline
    No biomarker
    Fallopian Tube Cancer
    VAC
    Sensitive: A2 - Guideline
    No biomarker
    Fallopian Tube Cancer
    EP
    Sensitive: A2 - Guideline
    TMB-H
    Fallopian Tube Cancer
    pembrolizumab
    Sensitive: A2 - Guideline
    No biomarker
    Fallopian Tube Cancer
    bevacizumab + olaparib
    Sensitive: A2 - Guideline
    No biomarker
    Fallopian Tube Cancer
    cisplatin + gemcitabine
    Sensitive: A2 - Guideline
    No biomarker
    Fallopian Tube Cancer
    OMP-305B83
    Sensitive: B - Late Trials
    No biomarker
    Fallopian Tube Cancer
    STRO-002
    Sensitive: B - Late Trials
    PD-L1 expression
    Fallopian Tube Cancer
    pembrolizumab
    Sensitive: C1 - Off-label
    HRD + BRCA2 mutation
    Fallopian Tube Cancer
    niraparib
    Sensitive: C3 – Early Trials
    HRD + BRCA1 mutation
    Fallopian Tube Cancer
    niraparib
    Sensitive: C3 – Early Trials
    TUBB3 expression
    Fallopian Tube Cancer
    bevacizumab + ixabepilone
    Resistant: C3 – Early Trials